title: Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
authors.forename: Faye A H
authors.initials: FA
authors.lastname: Cooles
authors.forename: Graham H
authors.initials: GH
authors.lastname: Jackson
authors.forename: Geetha
authors.initials: G
authors.lastname: Menon
authors.forename: John D
authors.initials: JD
authors.lastname: Isaacs
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D015551:Autoimmunity / Q000502:physiology; D001706:Biopsy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004279:DNA, Viral / Q000097:blood; D004317:Doxorubicin / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000502:physiology*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000473:pathology; D017285:Polymyositis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D004279:DNA, Viral; D000074323:Alemtuzumab; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone